Pacira Biosciences, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on December 9, 2021, covering events occurring on December 6 and December 7, 2021. The filing follows the Company's completion of the acquisition of Flexion Therapeutics, Inc. on November 19, 2021.
Key Financial Metrics and Obligations
- New Debt Facility: Entered into a Credit Agreement for a single-advance Term Loan B facility of $375.0 million.
- Interest Rates: Alternate Base Rate plus 6.00% or Adjusted Term SOFR Rate plus 7.00%.
- Maturity Date: December 7, 2026.
- Collateral: Secured by substantially all assets of the Company and subsidiary guarantors.
- Convertible Notes: Offered to repurchase Flexion's 3.375% Convertible Senior Notes due 2024 at 100% of principal plus accrued interest.
Note: This filing does not provide revenue, profit, cash flow, or margin data for the reporting period.
Material Changes
The primary material change is the incurrence of $375.0 million in new debt to replenish funds used for the Flexion Therapeutics acquisition. Additionally, the Company initiated a tender offer to repurchase outstanding convertible notes from the acquired entity.
Outlook, Risks, and Contingencies
The Credit Agreement includes customary affirmative and negative covenants, financial covenants, and events of default. The Company retains the option to request incremental term facilities subject to certain conditions. The repurchase offer for the Flexion Notes is subject to the terms and conditions set forth in the Fundamental Change Company Notice.
Investor Verification Checklist
- Review the full Credit Agreement (Exhibit 10.1) for specific financial covenants and default triggers.
- Verify the final acceptance rate and total cash outflow for the Flexion Notes repurchase offer.
- Monitor the Company's liquidity position post-closing of the $375.0 million term loan.
- Confirm the impact of the new debt service obligations on future cash flow projections.